| Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 5007 | 2011 |
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ... New England Journal of Medicine 369 (8), 722-731, 2013 | 2071 | 2013 |
| Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo … K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ... The lancet oncology 13 (10), 983-992, 2012 | 1677 | 2012 |
| Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) ND James, MR Spears, NW Clarke, DP Dearnaley, JS De Bono, J Gale, ... European urology 67 (6), 1028-1038, 2015 | 511 | 2015 |
| Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling E Avizienyte, AW Wyke, RJ Jones, GW McLean, MA Westhoff, VG Brunton, ... Nature cell biology 4 (8), 632-638, 2002 | 462 | 2002 |
| Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer MD Michaelson, S Oudard, YC Ou, L Sengeløv, F Saad, N Houede, ... Journal of Clinical Oncology 32 (2), 76-82, 2014 | 203 | 2014 |
| Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the … C Le Péchoux, A Laplanche, C Faivre-Finn, T Ciuleanu, R Wanders, ... Annals of oncology 22 (5), 1154-1163, 2011 | 198 | 2011 |
| Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging MO Leach, B Morgan, PS Tofts, DL Buckley, W Huang, MA Horsfield, ... European radiology 22 (7), 1451-1464, 2012 | 184 | 2012 |
| Adhesion-linked kinases in cancer; emphasis on src, focal adhesion kinase and PI 3-kinase RJ Jones, VG Brunton, MC Frame European Journal of Cancer 36 (13), 1595-1606, 2000 | 160 | 2000 |
| Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal AJ Muinonen-Martin, O Susanto, Q Zhang, E Smethurst, WJ Faller, ... | 140 | 2014 |
| Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration … K Fizazi, R Jones, S Oudard, E Efstathiou, F Saad, R de Wit, J De Bono, ... Journal of Clinical Oncology 33 (7), 723-731, 2015 | 134 | 2015 |
| Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study D Olmos, D Brewer, J Clark, DC Danila, C Parker, G Attard, M Fleisher, ... The lancet oncology 13 (11), 1114-1124, 2012 | 131 | 2012 |
| Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised … F Saad, K Fizazi, V Jinga, E Efstathiou, PC Fong, LL Hart, R Jones, ... The Lancet Oncology 16 (3), 338-348, 2015 | 115 | 2015 |
| Elevated c-Src is linked to altered cell–matrix adhesion rather than proliferation in KM12C human colorectal cancer cells RJ Jones, E Avizienyte, AW Wyke, DW Owens, VG Brunton, MC Frame British journal of cancer 87 (10), 1128-1135, 2002 | 107 | 2002 |
| A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or … RJ Jones, RE Hawkins, MM Eatock, DR Ferry, FALM Eskens, HJ Wilke, ... Cancer chemotherapy and pharmacology 61 (3), 435-441, 2008 | 90 | 2008 |
| Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis JA Ford, R Jones, A Elders, C Mulatero, P Royle, P Sharma, F Stewart, ... European Journal of Cancer 49 (2), 416-430, 2013 | 72 | 2013 |
| Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre … Y Loriot, K Fizazi, RJ Jones, J Van den Brande, RL Molife, A Omlin, ... Investigational new drugs 32 (5), 995-1004, 2014 | 68 | 2014 |
| Sunitinib and other targeted therapies for renal cell carcinoma T Powles, S Chowdhury, R Jones, M Mantle, P Nathan, A Bex, L Lim, ... British journal of cancer 104 (5), 741-745, 2011 | 67 | 2011 |
| Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study C Twelves, JM Trigo, R Jones, F De Rosa, A Rakhit, S Fettner, T Wright, ... European journal of cancer 44 (3), 419-426, 2008 | 63 | 2008 |
| Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study T Eisen, Y Shparyk, N Macleod, R Jones, G Wallenstein, G Temple, ... Investigational new drugs 31 (5), 1283-1293, 2013 | 56 | 2013 |
